Abstract
People with substance use disorders (SUD) have a high prevalence of chronic hepatitis C virus (HCV) infection and mental health disorders. We aimed to assess the impact of integrated HCV treatment on psychological distress measured by Hopkins-symptom-checklist-10 (SCL-10). This multi-center randomized controlled trial evaluated psychological distress as a secondary outcome of integrated HCV treatment (INTRO-HCV trial). From 2017 to 2019, 289 participants were randomly assigned to receive either integrated or standard HCV treatment with direct-acting antiviral therapy. Integrated HCV treatment was delivered in eight decentralized outpatient opioid agonist therapy clinics and two community care centers; standard treatment was delivered in internal medicine outpatient clinics at centralized hospitals. Participants in the integrated treatment arm had a sustained virologic response of 93% compared to 73% for those in standard treatment arm. Psychological distress was assessed using SCL-10 prior to initiation of HCV treatment and 12 weeks after treatment completion. The mean SCL-10 score prior to HCV treatment was 2.2 (standard deviation [SD]: 0.7) for patients receiving integrated HCV treatment and 2.2 (SD: 0.8) for those receiving standard HCV treatment. Twelve weeks after the end of treatment, the mean SCL-10 score change was − 0.1 (− 0.3;0.0) in the integrated compared to the standard arm. Psychological distress did not substantially change during the treatment period and was not significantly different between the treatment arms.
| Original language | English |
|---|---|
| Article number | 816 |
| Number of pages | 8 |
| Journal | Scientific Reports |
| Volume | 14 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 8 Jan 2024 |
Bibliographical note
Funding Information:We thank Nina Elisabeth Eltvik, Christer Kleppe, Rafael Alexander Leiva, and Christian Ohldieck for valuable help and input during the planning and preparation phases. We also thank the INTRO-HCV Study Group for important contribution relating to data collection. AGL and PV acknowledge support from the National Institute for Health and Care Research (NIHR) Health Protection Research Unit (HPRU) in Behavioural Science and Evaluation at the University of Bristol (NIHR200877). AGL and PV acknowledge support from the Well- come Trust (WT 220866/Z/20/Z) and UK NIHR (NIHR133208). INTRO-HCV Study Group participating investigators: Bergen: Christer Frode Aas, Vibeke Bråthen Buljovcic, Fatemeh Chalabianloo, Jan Tore Daltveit, Silvia Eiken Alpers, Lars T. Fadnes (principal investigator), Trude Fondenes Eriksen, Per Gundersen, Velinda Hille, Kristin Holmelid Håberg, Kjell Arne Johansson, Rafael Alexander Leiva, Siv-Elin Leirvåg Carlsen, Martine Lepsøy Bonnier, Lennart Lorås, Else-Marie Løberg, Mette Hegland Nordbotn, Cathrine Nygård, Maria Olsvold, Christian Ohldieck, Lillian Sivertsen, Hugo Torjussen, Jørn Henrik Vold, Jan-Magnus Økland. Stavanger: Tone Lise Eielsen, Nancy Laura Ortega Maldonado, Ewa Joanna Wilk. proLAR: Ronny Bjørnestad, Ole Jørgen Lygren, Marianne Cook Pierron. Oslo: Olav Dalgard, Håvard Midgard, Svetlana Skurtveit. Bristol: Aaron G. Lim, Peter Vickerman.
Funding Information:
Open access funding provided by University of Bergen. This work was supported by The Norwegian Research Council (BEHANDLING, contract no 269855); and the Western Norway Regional Health Authority («Åpen prosjektstøtte») with Department of Addiction Medicine, Haukeland University Hospital, Bergen, Norway as responsible institution. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The authors were funded by their respective affiliations.
Funding Information:
We thank Nina Elisabeth Eltvik, Christer Kleppe, Rafael Alexander Leiva, and Christian Ohldieck for valuable help and input during the planning and preparation phases. We also thank the INTRO-HCV Study Group for important contribution relating to data collection. AGL and PV acknowledge support from the National Institute for Health and Care Research (NIHR) Health Protection Research Unit (HPRU) in Behavioural Science and Evaluation at the University of Bristol (NIHR200877). AGL and PV acknowledge support from the Well- come Trust (WT 220866/Z/20/Z) and UK NIHR (NIHR133208). INTRO-HCV Study Group participating investigators: Bergen: Christer Frode Aas, Vibeke Bråthen Buljovcic, Fatemeh Chalabianloo, Jan Tore Daltveit, Silvia Eiken Alpers, Lars T. Fadnes (principal investigator), Trude Fondenes Eriksen, Per Gundersen, Velinda Hille, Kristin Holmelid Håberg, Kjell Arne Johansson, Rafael Alexander Leiva, Siv-Elin Leirvåg Carlsen, Martine Lepsøy Bonnier, Lennart Lorås, Else-Marie Løberg, Mette Hegland Nordbotn, Cathrine Nygård, Maria Olsvold, Christian Ohldieck, Lillian Sivertsen, Hugo Torjussen, Jørn Henrik Vold, Jan-Magnus Økland. Stavanger: Tone Lise Eielsen, Nancy Laura Ortega Maldonado, Ewa Joanna Wilk. proLAR: Ronny Bjørnestad, Ole Jørgen Lygren, Marianne Cook Pierron. Oslo: Olav Dalgard, Håvard Midgard, Svetlana Skurtveit. Bristol: Aaron G. Lim, Peter Vickerman.
Publisher Copyright:
© 2024, The Author(s).
